CD33 and acute myeloid leukemia: The ongoing first-in-human trial of SC-DARIC33 for children and young adults with relapsed or refractory CD33+ AML will provide clinical and correlative data supporting the pharmacologic control of CAR T products, as well as AML- and myeloid cell–targeting attributes of this next-generation cellular therapeutic.